- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
52
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
52 companies
Madrigal Pharmaceuticals
Market Cap: US$11.5b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$496.97
7D
-1.6%
1Y
53.1%
Arcutis Biotherapeutics
Market Cap: US$3.2b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$26.70
7D
-0.1%
1Y
94.7%
Ardelyx
Market Cap: US$1.6b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$7.76
7D
10.2%
1Y
58.0%
Marker Therapeutics
Market Cap: US$35.3m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$2.19
7D
20.3%
1Y
1.4%
Legend Biotech
Market Cap: US$4.3b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$20.76
7D
-10.8%
1Y
-44.6%
ARS Pharmaceuticals
Market Cap: US$1.1b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$10.45
7D
-7.6%
1Y
-22.5%
Lineage Cell Therapeutics
Market Cap: US$399.8m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.66
7D
-2.4%
1Y
145.9%
Achieve Life Sciences
Market Cap: US$292.3m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$5.42
7D
-3.4%
1Y
76.5%
Soleno Therapeutics
Market Cap: US$2.3b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$43.56
7D
2.6%
1Y
-10.1%
Aldeyra Therapeutics
Market Cap: US$285.8m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$4.99
7D
17.7%
1Y
-0.8%
Pelthos Therapeutics
Market Cap: US$69.0m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$23.03
7D
-8.2%
1Y
-14.7%
Capricor Therapeutics
Market Cap: US$1.3b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$24.31
7D
-1.9%
1Y
63.2%
RenovoRx
Market Cap: US$38.1m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.00
7D
-5.9%
1Y
-32.6%
AC Immune
Market Cap: US$347.3m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.32
7D
-10.3%
1Y
25.3%
Viridian Therapeutics
Market Cap: US$3.1b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$32.29
7D
-4.4%
1Y
76.0%
Citius Oncology
Market Cap: US$89.0m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$1.15
7D
4.5%
1Y
-12.9%
Longeveron
Market Cap: US$11.3m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.53
7D
-4.4%
1Y
-69.0%
Precigen
Market Cap: US$1.6b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.46
7D
1.1%
1Y
294.7%
Syndax Pharmaceuticals
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$20.52
7D
-4.3%
1Y
46.6%
Caris Life Sciences
Market Cap: US$7.4b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$25.48
7D
-3.6%
1Y
n/a
Vera Therapeutics
Market Cap: US$3.3b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$44.83
7D
-8.7%
1Y
33.0%
Altimmune
Market Cap: US$462.8m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$4.23
7D
5.5%
1Y
-38.1%
Insmed
Market Cap: US$34.9b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$156.32
7D
-4.4%
1Y
99.3%
Rhythm Pharmaceuticals
Market Cap: US$6.8b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$102.59
7D
-4.8%
1Y
78.4%
Roivant Sciences
Market Cap: US$16.0b
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
ROIV
US$22.98
7D
-3.5%
1Y
105.9%
Praxis Precision Medicines
Market Cap: US$9.0b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$312.60
7D
4.7%
1Y
292.8%
BioRestorative Therapies
Market Cap: US$9.9m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.15
7D
-2.6%
1Y
-50.3%
Unicycive Therapeutics
Market Cap: US$141.4m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$6.60
7D
-0.2%
1Y
5.8%
Amicus Therapeutics
Market Cap: US$4.4b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.31
7D
-0.07%
1Y
50.5%
Zymeworks
Market Cap: US$1.8b
A clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).
ZYME
US$23.95
7D
-2.7%
1Y
63.3%
Savara
Market Cap: US$1.4b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$6.19
7D
3.2%
1Y
123.5%
Day One Biopharmaceuticals
Market Cap: US$1.2b
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$12.07
7D
12.5%
1Y
-2.5%
Prelude Therapeutics
Market Cap: US$151.6m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$1.82
7D
-19.5%
1Y
55.6%
Cogent Biosciences
Market Cap: US$6.1b
A biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$39.90
7D
5.6%
1Y
386.6%
Fortress Biotech
Market Cap: US$108.0m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$3.46
7D
5.5%
1Y
91.2%
Creative Medical Technology Holdings
Market Cap: US$6.9m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$1.95
7D
5.4%
1Y
-20.7%